RxDoctor Payments Data

Sushil Duddempudi, MD

Gastroenterology · Round Rock, TXNPI 1518158427

Payments from drug & device makers

$39,324in general payments, 2019–2025

Across 491 payments — averaging $80.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$29K
  • AbbVie$3K
  • Boston Scientific$2K
  • Medtronic$522
  • Bristol Myers Squibb$509
  • Pfizer$416
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$23,22059%
  • Travel & lodging$5,11213%
  • Food & beverage$10,91228%
  • Education$800%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,324 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$108,391
Medicare patients
419
Services billed
860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase47$156,090
LinzessLinaclotide75$62,226
XifaxanRifaximin22$58,505
ViberziEluxadoline23$46,044
TrulancePlecanatide16$24,468
VoqueznaVonoprazan Fumarate11$9,738
Omeprazole714$8,960
Dexlansoprazole DrDexlansoprazole22$8,179
Mesalamine12$7,976
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C53$7,240
Dicyclomine Hcl85$2,147
Pantoprazole Sodium124$1,692
Esomeprazole Magnesium37$1,630
Rabeprazole Sodium26$950
Sucralfate13$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$3,178$264,360145 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$380$90,21291 claims
Phathom Pharmaceuticals, Inc.Voquezna$29,178$9,73811 claims
SandozLansoprazole$20$75022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →